Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%

Summary of findings: pioglitazone monotherapy vs placebo

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
2.38 [0.54, 10.5]
4 studies · 1156 participants
Very low

Summary of findings: pioglitazone monotherapy vs placebo

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy may leads to lower incidence of T2DM (N) Diagnostic criteria: 3 studies applied the WHO… compared with placebo (low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 0.4 [0.17, 0.95]
6 studies · 1395 participants
Low

Summary of findings: pioglitazone monotherapy vs placebo

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
3 [0.32, 28.22]
2 studies · 187 participants
Very low

Summary of findings: pioglitazone monotherapy vs placebo

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes cardiovascular mortality (N) compared with placebo (very low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 5.14 [0.25, 106.28]
4 studies · 1156 participants
Very low

Summary of findings: pioglitazone monotherapy vs placebo

Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes non‐fatal myocardial infarction/stroke (N) compared with placebo (very low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 1.97 [0.18, 21.65]
3 studies · 789 participants
Very low

Summary of findings: pioglitazone monotherapy vs placebo

Health‐related quality of life · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs placebo

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found